Pieris Total Assets from 2010 to 2024

PIRS Stock

USD 16.83 0.24 1.41%

Pieris Pharmaceuticals Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets will likely drop to about 36.7 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2013-12-31

Previous Quarter

25.1 M

Current Value

20.5 M

Quarterly Volatility

53.9 M

Yuan Drop

Covid

Check Pieris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pieris Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 12.3 M or Selling General Administrative of 13.5 M, as well as many indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or PTB Ratio of 0.58. Pieris financial statements analysis is a perfect complement when working with Pieris Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Pieris Pharmaceuticals Correlation against competitors.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Latest Pieris Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Pieris Pharmaceuticals over the last few years. Total assets refers to the total amount of Pieris Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Pieris Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Pieris Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pieris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 38.68 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Pieris Total Assets Regression Statistics

	Arithmetic Mean	63,045,593
	Geometric Mean	39,850,161
	Coefficient Of Variation	85.71
	Mean Deviation	48,280,059
	Median	36,746,000
	Standard Deviation	54,034,539
	Sample Variance	2919.7T
	Range	146.3M
	R-Value	0.57
	Mean Square Error	2119.3T
	R-Squared	0.33
	Significance	0.03
	Slope	6,898,480
	Total Sum of Squares	40876.2T

Pieris Total Assets History

	2024	36.7 M
	2023	38.7 M
	2022	95.5 M
	2021	153.6 M
	2020	105 M
	2019	141.1 M
	2018	141.3 M

Other Fundumenentals of Pieris Pharmaceuticals

Intangibles To Total Assets

Pieris Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Current Deferred Revenue	Short Term Investments	Capital Surpluse	Property Plant Equipment	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.8	-0.89	-0.49	0.77	0.55	0.97	0.97	0.06	0.33	0.77	0.73	0.65	0.57	0.5	0.18	0.77	0.76	0.17
Total Stockholder Equity	0.8		-0.8	-0.62	0.82	0.13	0.63	0.83	0.16	0.39	1.0	0.49	0.44	0.75	0.62	-0.11	0.85	0.69	0.35
Net Debt	-0.89	-0.8		0.4	-0.66	-0.28	-0.83	-0.88	-0.13	-0.29	-0.77	-0.62	-0.37	-0.5	-0.41	-0.18	-0.71	-0.75	-0.15
Retained Earnings	-0.49	-0.62	0.4		-0.56	-0.11	-0.39	-0.55	0.09	-0.76	-0.66	-0.61	-0.25	-0.97	-0.92	0.59	-0.74	-0.13	-0.87
Accounts Payable	0.77	0.82	-0.66	-0.56		0.34	0.67	0.77	-0.07	0.44	0.81	0.44	0.47	0.62	0.61	-0.07	0.87	0.71	0.38
Net Receivables	0.55	0.13	-0.28	-0.11	0.34		0.66	0.51	0.35	0.06	0.11	0.63	0.6	0.15	0.06	0.21	0.12	0.17	-0.05
Total Liab	0.97	0.63	-0.83	-0.39	0.67	0.66		0.92	0.01	0.27	0.6	0.76	0.67	0.44	0.41	0.26	0.66	0.7	0.09
Total Current Assets	0.97	0.83	-0.88	-0.55	0.77	0.51	0.92		0.08	0.35	0.81	0.8	0.72	0.65	0.53	-0.03	0.82	0.79	0.22
Short Term Debt	0.06	0.16	-0.13	0.09	-0.07	0.35	0.01	0.08		-0.2	0.16	0.16	0.04	0.06	-0.23	0.06	-0.28	-0.18	-0.17
Common Stock	0.33	0.39	-0.29	-0.76	0.44	0.06	0.27	0.35	-0.2		0.44	0.48	0.15	0.68	0.67	-0.35	0.54	0.03	0.8
Net Tangible Assets	0.77	1.0	-0.77	-0.66	0.81	0.11	0.6	0.81	0.16	0.44		0.5	0.43	0.79	0.66	-0.18	0.86	0.66	0.41
Current Deferred Revenue	0.73	0.49	-0.62	-0.61	0.44	0.63	0.76	0.8	0.16	0.48	0.5		0.7	0.64	0.43	-0.21	0.55	0.37	0.43
Short Term Investments	0.65	0.44	-0.37	-0.25	0.47	0.6	0.67	0.72	0.04	0.15	0.43	0.7		0.33	0.14	-0.04	0.49	0.6	-0.02
Capital Surpluse	0.57	0.75	-0.5	-0.97	0.62	0.15	0.44	0.65	0.06	0.68	0.79	0.64	0.33		0.89	-0.58	0.78	0.24	0.78
Property Plant Equipment	0.5	0.62	-0.41	-0.92	0.61	0.06	0.41	0.53	-0.23	0.67	0.66	0.43	0.14	0.89		-0.51	0.79	0.22	0.73
Short Long Term Debt	0.18	-0.11	-0.18	0.59	-0.07	0.21	0.26	-0.03	0.06	-0.35	-0.18	-0.21	-0.04	-0.58	-0.51		-0.31	0.14	-0.54
Net Invested Capital	0.77	0.85	-0.71	-0.74	0.87	0.12	0.66	0.82	-0.28	0.54	0.86	0.55	0.49	0.78	0.79	-0.31		0.75	0.48
Net Working Capital	0.76	0.69	-0.75	-0.13	0.71	0.17	0.7	0.79	-0.18	0.03	0.66	0.37	0.6	0.24	0.22	0.14	0.75		-0.16
Capital Stock	0.17	0.35	-0.15	-0.87	0.38	-0.05	0.09	0.22	-0.17	0.8	0.41	0.43	-0.02	0.78	0.73	-0.54	0.48	-0.16

Click cells to compare fundamentals

About Pieris Pharmaceuticals Financial Statements

Pieris Pharmaceuticals shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Pieris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Pieris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Pieris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	38.7 M	36.7 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC